Novo Nordisk A/S Stock Price, News & Analysis (NYSE:NVO)

$50.91 0.41 (0.81 %)
(As of 11/18/2017 01:41 AM ET)
Previous Close$50.91
Today's Range$51.05 - $50.52
52-Week Range$30.89 - $51.05
Volume1.12 million shs
Average Volume2.14 million shs
Market Capitalization$99.16 billion
P/E Ratio21.76
Dividend Yield1.64%
Beta0.65

About Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S logoNovo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Pharmaceuticals - NEC
  • Symbol: NYSE:NVO
  • CUSIP: N/A
  • Web: www.novonordisk.com
Debt:
  • Current Ratio: 1.27%
  • Quick Ratio: 0.93%
Price-To-Earnings:
  • Trailing P/E Ratio: 21.76
  • Forward P/E Ratio: 21.48
  • P/E Growth: 2.98
Sales & Book Value:
  • Annual Sales: $15.97616 billion
  • Price / Sales: 8.13
  • Cash Flow: $2.38 per share
  • Price / Cash: 21.37
  • Book Value: $2.91 per share
  • Price / Book: 17.49
Dividend:
  • Annual Dividend: $0.82
  • Dividend Yield: 1.6%
Profitability:
  • Trailing EPS: $2.45
  • Net Income: $5.63565 billion
  • Net Margins: 34.11%
  • Return on Equity: 84.64%
  • Return on Assets: 39.57%
Misc:
  • Employees: 41,971
  • Outstanding Shares: 2,550,000,000
 

Frequently Asked Questions for Novo Nordisk A/S (NYSE:NVO)

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared an annual dividend on Wednesday, August 9th. Investors of record on Monday, August 21st will be paid a dividend of $0.336 per share on Tuesday, August 29th. This represents a yield of 1.07%. The ex-dividend date is Friday, August 18th. This is an increase from Novo Nordisk A/S's previous annual dividend of $0.33. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S declared that its Board of Directors has approved a stock buyback plan on Thursday, April 6th 2017, which allows the company to repurchase shares, according to EventVestor. This repurchase authorization allows the company to buy up to 18.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's management believes its stock is undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Friday, April, 29th. The company reported $0.55 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.53 by $0.02. The company had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $4.07 billion. Novo Nordisk A/S had a net margin of 34.11% and a return on equity of 84.64%. View Novo Nordisk A/S's Earnings History.

When will Novo Nordisk A/S make its next earnings announcement?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Novo Nordisk A/S.

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:

  • Goran A. Ando M.D., Chairman of the Board (Age 68)
  • Lars Fruergaard Joergensen, President, Chief Executive Officer (Age 50)
  • Jeppe Christiansen, Vice Chairman of the Board (Age 57)
  • Jesper Brandgaard, Chief Financial Officer, Executive Vice President (Age 53)
  • Maziar Mike Doustdar, Executive Vice President, International Operations (Age 46)
  • Mads Krogsgaard Thomsen, Chief Science Officer, Executive Vice President (Age 56)
  • Doug Langa, Executive Vice President, North America Operations
  • Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate Affairs
  • Henrik Ehlers Wulff, Executive Vice President, Product Supply (Age 46)
  • Liselotte Hyveled, Director, Employee Representative (Age 51)

Who owns Novo Nordisk A/S stock?

Novo Nordisk A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.62%), Folketrygdfondet (0.28%), Fayez Sarofim & Co. (0.20%), Ameriprise Financial Inc. (0.10%), Saratoga Research & Investment Management (0.06%) and Bank of New York Mellon Corp (0.05%). View Institutional Ownership Trends for Novo Nordisk A/S.

Who sold Novo Nordisk A/S stock? Who is selling Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was sold by a variety of institutional investors in the last quarter, including River Road Asset Management LLC, Capital Bank & Trust Co, Wells Fargo & Company MN, Assetmark Inc., Capital International Investors, Fayez Sarofim & Co., Ameriprise Financial Inc. and Scout Investments Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

Who bought Novo Nordisk A/S stock? Who is buying Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Orbimed Advisors LLC, Folketrygdfondet, CI Investments Inc., Point72 Asset Management L.P., Canada Pension Plan Investment Board, Aperio Group LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy Novo Nordisk A/S stock?

Shares of Novo Nordisk A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of Novo Nordisk A/S stock can currently be purchased for approximately $50.91.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $99.16 billion and generates $15.97616 billion in revenue each year. The company earns $5.63565 billion in net income (profit) each year or $2.45 on an earnings per share basis. Novo Nordisk A/S employs 41,971 workers across the globe.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, BAGSVAERD, 2880, Denmark. The company can be reached via phone at +45-44-448888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Novo Nordisk A/S (NYSE:NVO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 4 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 1.67)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Novo Nordisk A/S (NYSE:NVO)

Price Target History for Novo Nordisk A/S (NYSE:NVO)

Analysts' Ratings History for Novo Nordisk A/S (NYSE:NVO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017BNP ParibasDowngradeOutperform -> NeutralHighView Rating Details
9/6/2017Bank of America CorporationUpgradeUnderperform -> NeutralLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
1/3/2017J P Morgan Chase & CoDowngradeNeutral -> UnderweightN/AView Rating Details
12/20/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
12/1/2016Credit Suisse GroupReiterated RatingHoldN/AView Rating Details
10/31/2016DNB MarketsDowngradeBuy -> HoldN/AView Rating Details
10/31/2016Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/13/2016Pacific CrestUpgradeNeutral -> OutperformN/AView Rating Details
9/12/2016Deutsche Bank AGUpgradeHold -> BuyN/AView Rating Details
9/1/2016Morgan StanleyDowngradeOverweight -> Equal WeightN/AView Rating Details
6/28/2016The Goldman Sachs Group, Inc.DowngradeConviction-Buy -> BuyN/AView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Novo Nordisk A/S (NYSE:NVO)

Earnings by Quarter for Novo Nordisk A/S (NYSE:NVO)

Earnings History by Quarter for Novo Nordisk A/S (NYSE NVO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018        
4/29/2016Q1$0.53$0.55$4.07 billion$4.02 billionViewListenView Earnings Details
10/29/2015Q3$0.47$0.49$4.03 billion$3.99 billionViewN/AView Earnings Details
4/30/2015Q1$0.39$0.45$25.13 billion$25.20 billionViewN/AView Earnings Details
1/30/2015Q4$2.48$0.38$24.67 billion$24.59 billionViewN/AView Earnings Details
8/7/2014Q2$2.60$0.48$21.86 billion$21.63 billionViewN/AView Earnings Details
5/1/2014Q1$0.44$0.45$20.83 billion$20.30 billionViewN/AView Earnings Details
1/28/2014Q413$0.42ViewN/AView Earnings Details
10/31/2013Q1$12.11$2.20$21.04 billion$20.51 billionViewN/AView Earnings Details
8/8/2013Q1$11.97$12.45$21.09 billion$21.38 billionViewN/AView Earnings Details
5/1/2013$10.67$10.98$19.73 billion$19.98 billionViewN/AView Earnings Details
1/31/2013$9.77$10.53$20.83 billion$20.96 billionViewN/AView Earnings Details
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novo Nordisk A/S (NYSE:NVO)
2017 EPS Consensus Estimate: $2.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.52$0.52$0.52
Q2 20172$0.52$0.60$0.56
Q3 20171$0.55$0.55$0.55
Q4 20171$0.56$0.56$0.56
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novo Nordisk A/S (NYSE:NVO)

Most Recent Dividend:8/29/2017
Annual Dividend:$0.82
Dividend Yield:1.61%
Dividend Growth:31.50% (3 Year Average)
Payout Ratio:33.47% (Trailing 12 Months of Earnings)
34.60% (Based on This Year's Estimates)
32.93% (Based on Next Year's Estimates)
Track Record:20 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Novo Nordisk A/S (NYSE:NVO)

Dividend History by Quarter for Novo Nordisk A/S (NYSE NVO)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/9/2017annual$0.341.07%8/18/20178/21/20178/29/2017
2/7/2017annual$0.661.99%3/23/20173/27/20174/4/2017
8/8/2016$0.338/11/20168/15/20168/23/2016
2/16/2016Annual$0.703/18/20163/22/20163/30/2016
3/17/2014annual$0.841.83%3/21/20143/25/20144/2/2014
2/27/2013annual$3.181.81%3/21/20133/25/20134/2/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novo Nordisk A/S (NYSE NVO)

Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 6.01%
Insider Trades by Quarter for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Insider Trades by Quarter for Novo Nordisk A/S (NYSE NVO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2017Eric S SprottInsiderBuy50,000$8.34$417,000.00
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.28$31,876.98
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Novo Nordisk A/S (NYSE NVO)

Source:
DateHeadline
Novo Nordisk: Q3 2017 Results Show Strong Future Potential - Seeking AlphaNovo Nordisk: Q3 2017 Results Show Strong Future Potential - Seeking Alpha
seekingalpha.com - November 18 at 9:23 AM
Novo Nordisk A/S (NVO) a Strong Buy on High-Level Earnings Momentum - Investorplace.comNovo Nordisk A/S (NVO) a Strong Buy on High-Level Earnings Momentum - Investorplace.com
investorplace.com - November 18 at 9:23 AM
Novo Nordisk A/S (NVO) a Strong Buy on High-Level Earnings MomentumNovo Nordisk A/S (NVO) a Strong Buy on High-Level Earnings Momentum
investorplace.com - November 17 at 2:42 PM
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day - NasdaqNovo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day - Nasdaq
www.nasdaq.com - November 15 at 6:57 AM
Pre-Market Technical Recap on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, United Therapeutics, and ... - PR Newswire (press release)Pre-Market Technical Recap on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, United Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - November 15 at 6:57 AM
Novo Nordisk A/S (NVO) Insider Eric S. Sprott Acquires 50,000 SharesNovo Nordisk A/S (NVO) Insider Eric S. Sprott Acquires 50,000 Shares
www.americanbankingnews.com - November 13 at 4:51 PM
ETFs with exposure to Novo Nordisk A/S : November 9, 2017ETFs with exposure to Novo Nordisk A/S : November 9, 2017
finance.yahoo.com - November 12 at 11:07 AM
High-End Earnings Visibility Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong BuyHigh-End Earnings Visibility Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong Buy
investorplace.com - November 10 at 11:26 AM
Novo Nordisk A/S (NVO) Receives Average Rating of "Hold" from AnalystsNovo Nordisk A/S (NVO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 9 at 8:30 AM
Novo Nordisk A/S Slogs Through the YearNovo Nordisk A/S Slogs Through the Year
www.fool.com - November 7 at 4:22 PM
Foreign Stock Roundup: Alibaba, Sinopec, BP, Novo Nordisk Beat on Earnings - NasdaqForeign Stock Roundup: Alibaba, Sinopec, BP, Novo Nordisk Beat on Earnings - Nasdaq
www.nasdaq.com - November 7 at 7:59 AM
Exceptional Quant Score Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong BuyExceptional Quant Score Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong Buy
investorplace.com - November 3 at 11:26 AM
Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales - NasdaqNovo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales - Nasdaq
www.nasdaq.com - November 2 at 7:05 AM
Novo Nordisk A/S - Share repurchase programme Copenhagen ... - GlobeNewswire (press release)Novo Nordisk A/S - Share repurchase programme Copenhagen ... - GlobeNewswire (press release)
globenewswire.com - November 1 at 7:05 AM
Diabetes drugmaker Novo Nordisk expects low to mid single-digit growth in 2018​Diabetes drugmaker Novo Nordisk expects low to mid single-digit growth in 2018​
finance.yahoo.com - November 1 at 7:05 AM
Novo Nordisk will continue to deliver on 2017 plans, CFO ...Novo Nordisk will continue to deliver on 2017 plans, CFO ...
finance.yahoo.com - November 1 at 7:05 AM
Drugmaker Novo Nordisk warns U.S. legislation could make business difficultDrugmaker Novo Nordisk warns U.S. legislation could make business difficult
finance.yahoo.com - November 1 at 7:05 AM
Drugmaker Novo Nordisk warns of U.S. legislation, cautious on 2018Drugmaker Novo Nordisk warns of U.S. legislation, cautious on 2018
finance.yahoo.com - November 1 at 7:05 AM
Jefferies Group Brokers Cut Earnings Estimates for Novo Nordisk A/S (NVO)Jefferies Group Brokers Cut Earnings Estimates for Novo Nordisk A/S (NVO)
www.americanbankingnews.com - October 30 at 11:52 AM
Novo Nordisk, Facing Pricing Pressure, Branches Out Beyond InsulinNovo Nordisk, Facing Pricing Pressure, Branches Out Beyond Insulin
finance.yahoo.com - October 30 at 2:56 AM
Novo Nordisk A/Ss (NVO) Solid Quant Score Makes it a Buy - Investorplace.comNovo Nordisk A/S's (NVO) Solid Quant Score Makes it a Buy - Investorplace.com
investorplace.com - October 28 at 10:20 AM
Novo Nordisk A/S (NVO) Lowered to "Hold" at Zacks Investment ResearchNovo Nordisk A/S (NVO) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 27 at 1:00 PM
Novo Nordisk A/S’s (NVO) Solid Quant Score Makes it a BuyNovo Nordisk A/S’s (NVO) Solid Quant Score Makes it a Buy
investorplace.com - October 27 at 11:32 AM
Jefferies Group Weighs in on Novo Nordisk A/Ss FY2017 Earnings (NVO)Jefferies Group Weighs in on Novo Nordisk A/S's FY2017 Earnings (NVO)
www.americanbankingnews.com - October 27 at 7:42 AM
Leerink Swann Equities Analysts Boost Earnings Estimates for Novo Nordisk A/S (NVO)Leerink Swann Equities Analysts Boost Earnings Estimates for Novo Nordisk A/S (NVO)
www.americanbankingnews.com - October 25 at 11:01 AM
FY2017 EPS Estimates for Novo Nordisk A/S Boosted by Leerink Swann (NVO)FY2017 EPS Estimates for Novo Nordisk A/S Boosted by Leerink Swann (NVO)
www.americanbankingnews.com - October 24 at 8:28 AM
Earnings Visibility Makes Novo Nordisk A/S (NVO) a BuyEarnings Visibility Makes Novo Nordisk A/S (NVO) a Buy
investorplace.com - October 20 at 11:19 AM
U.S. FDA panel backs approval of Novo Nordisk diabetes drugU.S. FDA panel backs approval of Novo Nordisk diabetes drug
finance.yahoo.com - October 19 at 6:59 AM
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutideNovo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide
finance.yahoo.com - October 19 at 6:59 AM
Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drugNovo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug
finance.yahoo.com - October 19 at 6:59 AM
Is Novo Nordisk Still A Buy?Is Novo Nordisk Still A Buy?
seekingalpha.com - October 17 at 3:28 AM
Novo Nordisk diabetes drug effective, no heart risk -FDA reviewNovo Nordisk diabetes drug effective, no heart risk -FDA review
finance.yahoo.com - October 17 at 3:28 AM
Novo Nordisk diabetes drug effective, preliminary FDA review findsNovo Nordisk diabetes drug effective, preliminary FDA review finds
finance.yahoo.com - October 17 at 3:28 AM
Novo Nordisk A/S (NVO) Given Consensus Rating of "Hold" by BrokeragesNovo Nordisk A/S (NVO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 15 at 11:04 AM
Contrasting Concordia International Corp. (CXRX) and Novo Nordisk A/S (NVO)Contrasting Concordia International Corp. (CXRX) and Novo Nordisk A/S (NVO)
www.americanbankingnews.com - October 13 at 6:22 AM
Pre-Market Most Active for Oct 10, 2017 : MNKD, NVDA, GSK, BABA, BAC, WMT, NVO, MU, CHL, TVIX, ERIC, ANAB - NasdaqPre-Market Most Active for Oct 10, 2017 : MNKD, NVDA, GSK, BABA, BAC, WMT, NVO, MU, CHL, TVIX, ERIC, ANAB - Nasdaq
www.nasdaq.com - October 11 at 5:21 AM
Novo Nordisk A/S (NVO) Downgraded to Hold at Zacks Investment ResearchNovo Nordisk A/S (NVO) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 9 at 12:40 PM
Novo Nordisk A/S’s (NVO) Stock Has Hold Recommendation Remain in PlaceNovo Nordisk A/S’s (NVO) Stock Has Hold Recommendation Remain in Place
investorplace.com - October 6 at 11:54 AM
Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan DealPharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal
finance.yahoo.com - October 6 at 10:02 AM
Novo Nordisk A/S - Share repurchase programme - GlobeNewswire (press release)Novo Nordisk A/S - Share repurchase programme - GlobeNewswire (press release)
globenewswire.com - October 3 at 8:37 AM
Striking Blood Sugar Balance is Critical for Canadians Living with DiabetesStriking Blood Sugar Balance is Critical for Canadians Living with Diabetes
finance.yahoo.com - October 3 at 8:36 AM
Novo Nordisks Fiasp Gets FDA Nod for Diabetes in AdultsNovo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults
www.zacks.com - October 2 at 7:20 PM
Status regarding Novo Nordisks holding of its own shares (30 September 2017)Status regarding Novo Nordisk's holding of its own shares (30 September 2017)
finance.yahoo.com - October 2 at 7:20 PM
Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in AdultsNovo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults
finance.yahoo.com - October 2 at 7:19 PM
Financial Analysis: XenoPort (XNPT) versus Novo Nordisk A/S (NVO)Financial Analysis: XenoPort (XNPT) versus Novo Nordisk A/S (NVO)
www.americanbankingnews.com - October 2 at 10:30 AM
Form 6-K NOVO NORDISK A S For: Sep 29Form 6-K NOVO NORDISK A S For: Sep 29
www.streetinsider.com - September 30 at 11:00 AM
Novo Nordisk diabetes drug approved in ChinaNovo Nordisk diabetes drug approved in China
www.marketwatch.com - September 28 at 2:27 AM
Novo Nordisk A/S (NVO) Lowered to Neutral at BNP ParibasNovo Nordisk A/S (NVO) Lowered to Neutral at BNP Paribas
www.americanbankingnews.com - September 25 at 4:44 PM
Comparing Novo Nordisk A/S (NVO) & Shire PLC (SHPG)Comparing Novo Nordisk A/S (NVO) & Shire PLC (SHPG)
www.americanbankingnews.com - September 23 at 4:20 PM
How Novo Nordisk Performed in the 1st Half of 2017How Novo Nordisk Performed in the 1st Half of 2017
finance.yahoo.com - September 22 at 11:58 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Novo Nordisk A/S (NYSE NVO) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.